Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes-Reference-Cited by-同舟云学术

Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes

Published:2021-12-10 Issue:1 Volume:19 Page:172-187
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Vasalou Christina¹^ORCID,Ferguson Douglas¹,Li Weimin²,Muse Victorine³,Gibbons Francis D.⁴,Sonzini Silvia²,Zhang Guangnong⁵,Pop-Damkov Petar⁶,Gangl Eric¹,Balachander Srividya B.⁷,Wen Shenghua¹,Schuller Alwin G.¹,Puri Sanyogitta²,Mazza Mariarosa²,Ashford Marianne²,Fretland Adrian J.⁸,McGinnity Dermot F.⁹,Jones Rhys D. O.⁹

Affiliation:

1. Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States

2. Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K.

3. Novo Nordisk Foundation Center for Protein Research, Copenhagen 2200, Denmark

4. Biogen, Cambridge, Massachusetts 02142, United States

5. Dicerna Pharmaceuticals, Inc, Lexington, Massachusetts 02421, United States

6. Takeda Pharmaceuticals, Cambridge, Massachusetts 02139, United States

7. Bristol-Myers Squibb, Cambridge, Massachusetts 02142, United States

8. Repare Therapeutics, Cambridge, Massachusetts 02142, United States

9. Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K.

Publisher

American Chemical Society (ACS)